검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells) National Cancer Institute (NCI)·CD19 ORR 94% |
|---|---|
Overview Program | Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Lymphoma, B-Cell; Lymphoma, Non-hodgkins |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Toxicology Major finding | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 94% |
Clinical ORR | 94% |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells) National Cancer Institute (NCI)·CD19 ORR 94% |
|---|---|
Overview Program | Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Lymphoma, B-Cell; Lymphoma, Non-hodgkins |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Toxicology Major finding | Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.. Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtage… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 94% |
Clinical ORR | 94% |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교